Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 3
2021 3
2022 4
2023 3
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Time to Uveitis Control with Methotrexate and Mycophenolate Mofetil.
Bui AD, Kong CL, Kelly NK, Rathinam SR, Gonzales JA, Thundikandy R, Kanakath A, Murugan B, Vedhanayaki R, Lim LL, Suhler EB, Al-Dhibi HA, Doan T, Acharya NR; First-Line Antimetabolites as Steroid-Sparing Treatment Research Group. Bui AD, et al. Among authors: vedhanayaki r. Ophthalmology. 2022 Jun;129(6):721-723. doi: 10.1016/j.ophtha.2022.01.020. Epub 2022 Jan 25. Ophthalmology. 2022. PMID: 35085661 No abstract available.
An Algorithm for the Diagnosis of Behçet Disease Uveitis in Adults.
Tugal-Tutkun I, Onal S, Stanford M, Akman M, Twisk JWR, Boers M, Oray M, Özdal P, Kadayifcilar S, Amer R, Rathinam SR, Vedhanayaki R, Khairallah M, Akova Y, Yalcindag F, Kardes E, Basarir B, Altan Ç, Özyazgan Y, Gül A. Tugal-Tutkun I, et al. Among authors: vedhanayaki r. Ocul Immunol Inflamm. 2021 Aug 18;29(6):1154-1163. doi: 10.1080/09273948.2020.1736310. Epub 2020 Apr 14. Ocul Immunol Inflamm. 2021. PMID: 32286112
Outcomes of Uveitic Macular Edema in the First-line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial.
Tsui E, Rathinam SR, Gonzales JA, Thundikandy R, Kanakath A, Balamurugan S, Vedhanayaki R, Lim LL, Suhler EB, Al-Dhibi HA, Doan T, Keenan J, Ebert CD, Kim E, Madow B, Porco TC, Acharya NR; FAST Research Group. Tsui E, et al. Among authors: vedhanayaki r. Ophthalmology. 2022 Jun;129(6):661-667. doi: 10.1016/j.ophtha.2022.02.002. Epub 2022 Feb 8. Ophthalmology. 2022. PMID: 35143800 Clinical Trial.
Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial.
Acharya NR, Rathinam SR, Thundikandy R, Kanakath A, Murugan SB, Vedhanayaki R, Gonzales JA, Lim LL, Suhler EB, Al-Dhibi HA, Doan T, Arellanes-Garcia L, Coyne A, Porco TC, Shantha JG; FAST Research Group. Acharya NR, et al. Among authors: vedhanayaki r. Am J Ophthalmol. 2024 Nov;267:100-111. doi: 10.1016/j.ajo.2024.06.004. Epub 2024 Jun 22. Am J Ophthalmol. 2024. PMID: 38909740 Clinical Trial.
Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial.
Rathinam SR, Gonzales JA, Thundikandy R, Kanakath A, Murugan SB, Vedhanayaki R, Lim LL, Suhler EB, Al-Dhibi HA, Doan T, Keenan JD, Rao MM, Ebert CD, Nguyen HH, Kim E, Porco TC, Acharya NR; FAST Research Group. Rathinam SR, et al. Among authors: vedhanayaki r. JAMA. 2019 Sep 10;322(10):936-945. doi: 10.1001/jama.2019.12618. JAMA. 2019. PMID: 31503307 Free PMC article. Clinical Trial.
Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial.
Kong CL, Kelly NK, Sundararajan M, Rathinam SR, Gonzales JA, Thundikandy R, Vedhanayaki R, Kanakath A, Murugan B, Doan T, Goldstein D, Al-Dhibi HA, Acharya NR. Kong CL, et al. Among authors: vedhanayaki r. Ocul Immunol Inflamm. 2022 Jan 2;30(1):198-202. doi: 10.1080/09273948.2020.1774906. Epub 2020 Aug 11. Ocul Immunol Inflamm. 2022. PMID: 32779952 Free PMC article. Clinical Trial.
Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial.
Reddy AK, Miller DC, Sura AA, Rathinam SR, Gonzales JA, Thundikandy R, Kanakath A, Murugan B, Vedhanayaki R, Lim LL, Suhler EB, Doan T, Al-Dhibi HA, Goldstein DA, Arellanes-Garcia L, Acharya NR. Reddy AK, et al. Among authors: vedhanayaki r. J Ophthalmic Inflamm Infect. 2023 Jun 9;13(1):29. doi: 10.1186/s12348-023-00350-5. J Ophthalmic Inflamm Infect. 2023. PMID: 37294447 Free PMC article.
Health- and Vision-Related Quality of Life in a Randomized Controlled Trial Comparing Methotrexate and Mycophenolate Mofetil for Uveitis.
Kelly NK, Chattopadhyay A, Rathinam SR, Gonzales JA, Thundikandy R, Kanakath A, Murugan SB, Vedhanayaki R, Cugley D, Lim LL, Suhler EB, Al-Dhibi HA, Ebert CD, Berlinberg EJ, Porco TC, Acharya NR; FAST Research Group. Kelly NK, et al. Among authors: vedhanayaki r. Ophthalmology. 2021 Sep;128(9):1337-1345. doi: 10.1016/j.ophtha.2021.02.024. Epub 2021 Mar 4. Ophthalmology. 2021. PMID: 33675850 Free PMC article. Clinical Trial.
13 results